Somatuline Autogel: Acromegaly Self/Partner Injection Study
Somatuline Autogel: Acromegaly Self/Partner Injection Study
The purpose of this study is to allow patients with acromegaly, or their partners, to learn
 how to successfully inject Somatuline Autogel at home. Ability to perform unsupervised
 injections whilst maintaining adequate disease control will be assessed.
Inclusion Criteria:

 -  The patient must have a clinical diagnosis of acromegaly

 -  The patient must have been tested and shown to have a GH level less than or equal to
 10 micrograms/L within 28 days prior to the baseline visit

 -  The patient must be currently treated with Somatuline Autogel and have been stable on
 their current dose for at least 6 months immediately prior to screening

 -  The patient must be able to store study medication in a refrigerator in their own home

 Exclusion Criteria:

 -  The patient has had pituitary surgery (adenomectomy) within 6 months prior to
 screening

 -  The patient has received pituitary radiotherapy within one year prior to screening

 -  The patient is likely to require pituitary surgery (adenomectomy) or to receive
 radiotherapy during the study period

 -  The patient is currently receiving a GH antagonist or a somatostatin analogue other
 than Somatuline Autogel